Introduction {#Sec1}
============

Asthma is a major chronic, non-infectious respiratory disease affecting more than 350 million people worldwide.^[@CR1]^ In Asia, the prevalence of asthma is 3--7% and is expected to rise.^[@CR2],[@CR3]^ In Japan, \~3 million people suffer from asthma, making it the leading chronic respiratory disease; severe asthma accounts for 7% of Japanese patients with asthma, and moderate asthma for 30%.^[@CR4],[@CR5]^ The burden of asthma in Asia is in line with global trends.^[@CR6],[@CR7]^ A cross-sectional observational study conducted in six countries from the Asia-Pacific region demonstrated considerable healthcare resource utilization (HCRU) and associated cost burden owing to chronic respiratory diseases (combined: asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and rhinosinusitis).^[@CR8]^ The socioeconomic burden for asthma, specifically in Asia, consists of individual reports from Thailand, South Korea, Singapore, Taiwan, and India.^[@CR9]--[@CR14]^ However, data focusing on HCRU in asthma patients from Japan are scarce. The Japan Medical Data Center (JMDC) Claims Database contains claims from insurance societies throughout Japan, whose population consists of employees and their family members (includes children and elderly relative beneficiaries who are not employed).^[@CR15]^ The study of treatment patterns and HCRU insurance claims may enhance awareness of asthma-related treatment decisions in real-world practice, and inform Japan's investments in future health policy. Therefore, the present study aimed to evaluate healthcare utilization and economic burden of asthma in Japan as well as to assess the impact of asthma severity (as defined by the Japanese Society of Allergology (JSA)^[@CR16]^) on healthcare utilization.

Results {#Sec2}
=======

Patient disposition {#Sec3}
-------------------

Of the 541,434 patients identified with asthma diagnosis from the JMDC database, 514,502 patients had confirmed prescriptions for asthma drugs approved in Japan (Supplementary Table [1](#MOESM1){ref-type="media"}). Of these, 40,143 patients received drugs recommended for JSA Step 4 severity, 403,047 patients received drugs recommended for Steps 1--3, and 71,312 patients were excluded as their prescription profiles for asthma did not meet the criteria for any treatment step. A total of 54,433 patients who met the inclusion criteria were included in the study; of these, 6914 (12.7%) were classified as severe asthma patients (JSA Step 4; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Patient disposition. JSA Japanese Society of Allergology

Baseline demographics and clinical characteristics {#Sec4}
--------------------------------------------------

Patient demographics and baseline characteristics are presented in Table [1](#Tab1){ref-type="table"}. The mean ± standard deviation (SD) age of patients in the severe asthma cohort (43.03 ± 12.20 years) was significantly higher (*P* \< 0.0001 (*t*-test)), compared with the non-severe asthma cohort (39.76 ± 11.98 years). There was a slightly higher proportion of female patients, compared with men in both cohorts; however, no significant differences in gender distribution were observed by asthma severity. Occurrence of comorbidities was significantly higher in severe asthma cohort versus non-severe asthma cohort, with recurrent respiratory infection being the most frequent comorbidity in both cohorts.Table 1Patient demographics and baseline characteristicsCharacteristicSevere asthma cohort (*N* = 6914)Non-severe asthma cohort (*N* = 47,519)*P* valueAge, years43.03 ± 12.2039.76 ± 11.98\<0.0001Gender, *n* (%) Men3150 (45.6)22,115 (46.5)0.127 Women3764 (54.4)25,404 (53.5)Member type, *n* (%) Employee4069 (58.9)29,212 (61.5)\<0.0001 Family2845 (41.1)18,307 (38.5)Quan--Charlson comorbidity index1.82 ± 2.021.08 ± 1.45\<0.001Comorbidities, *n* (%) Recurrent respiratory infection4329 (62.6)25,627 (53.9)\<0.001 Rhinitis/allergic rhinitis4046 (58.5)19,774 (41.6)\<0.001 Eczema2357 (34.1)12,344 (26.0)\<0.001 Sinus disease2015 (29.1)8571 (18.0)\<0.001 Gastroesophageal reflux936 (13.5)3707 (7.8)\<0.001 Pneumonia922 (13.3)3095 (6.5)\<0.001 Psychiatric disorder (depression, anxiety)710 (10.3)3259 (6.9)\<0.001 Cardiovascular disease (myocardial infarction, stroke, heart failure)587 (8.5)2178 (4.6)\<0.001 Osteoporosis244 (3.5)665 (1.4)\<0.001 Diabetes238 (3.4)942 (2.0)\<0.001 Inflammatory bowel disease169 (2.4)506 (1.1)\<0.001 Chronic obstructive pulmonary disease109 (1.6)195 (0.4)\<0.001 Obstructive sleep apnea100 (1.4)507 (1.1)0.013 Hyperglycemia65 (0.9)241 (0.5)\<0.001 Nasal polyps48 (0.7)71 (0.1)\<0.001 Food allergy and anaphylaxis40 (0.6)161 (0.3)0.004Data presented as mean ± SD unless otherwise specified*SD* standard deviation*P* values were calculated using *χ*^2^ test for categorical variables, *t*-test for continuous variables

Healthcare resource utilization {#Sec5}
-------------------------------

Overall, HCRU due to asthma and all-cause was high at baseline and the 12-month follow-up in both the cohorts. Patients in the severe asthma cohort had significantly higher mean HCRU in terms of hospitalizations, emergency room (ER) visits, outpatient visits, and prescriptions, compared with the non-severe asthma cohort at baseline and at the 12-month follow-up (all *P* \< 0.001 (*t*-test); Table [2](#Tab2){ref-type="table"}).

Incidence rate ratios (IRRs) of HCRU events were significantly higher in the severe cohort, compared with the non-severe cohort (*P* \< 0.001); these included higher incidences of all-cause hospitalizations, ER visits, inpatient and outpatient prescriptions, and outpatient visits (Fig. [2](#Fig2){ref-type="fig"}).Table 2Healthcare resource utilization (all-cause and asthma related) at baseline and follow-upBaseline (12 months before index date)Follow-up (12 months after index date)Severe asthma cohort (*N* = 6914)Non-severe asthma cohort (*N* = 47,519)*P* valueSevere asthma cohort (*N* = 6914)Non-severe asthma cohort (*N* = 47,519)*P* valueNumber of hospitalizationsAll cause0.2 ± 0.50.1 ± 0.3\<0.0010.2 ± 0.80.1 ± 0.3\<0.001Number of patients, *n* (%)820 (11.9)2535 (5.3)791 (11.4)2447 (5.1)Asthma related0.0 ± 0.20.0 ± 0.1\<0.0010.1 ± 0.30.0 ± 0.1\<0.001Number of patients, *n* (%)135 (2.0)146 (0.3)301 (4.4)394 (0.8)Length of stay, daysAll cause3.1 ± 18.10.6 ± 5.8\<0.0012.7 ± 18.30.7 ± 11.1\<0.001Number of patients, *n* (%)820 (11.9)2535 (5.3)791 (11.4)2447 (5.1)Asthma related0.4 ± 5.50.0 ± 2.0\<0.0011.0 ± 8.90.1 ± 3.7\<0.001Number of patients, *n* (%)135 (2.0)146 (0.3)301 (4.4)394 (0.8)Number of ER visitsAll cause1.3 ± 3.60.8 ± 2.3\<0.0011.8 ± 5.21.1 ± 2.8\<0.001Number of patients, *n* (%)2868 (41.5)15,721 (33.1)3304 (47.8)20,212 (42.5)Asthma related0.3 ± 1.40.1 ± 0.8\<0.0010.6 ± 2.10.4 ± 1.3\<0.001Number of patients, *n* (%)981 (14.2)2,699 (5.7)1605 (23.3)9420 (19.8)Number of outpatient visitsAll cause19.0 ± 22.110.9 ± 13.9\<0.00127.0 ± 26.214.5 ± 15.6\<0.001Number of patients, *n* (%)6753 (97.7)44,823 (94.3)6910 (99.9)47,515 (100.0)Asthma related5.0 ± 9.41.4 ± 4.2\<0.0019.6 ± 11.74.7 ± 6.6\<0.001Number of patients, *n* (%)4266 (61.7)15,295 (32.2)5964 (86.3)44,914 (94.5)Number of inpatient prescriptionAll cause0.2 ± 0.70.1 ± 0.4\<0.0010.3 ± 1.10.1 ± 0.4\<0.001Number of patients, *n* (%)692 (10.0)2508 (5.3)983 (14.2)2589 (5.4)Asthma related0.0 ± 0.30.0 ± 0.1\<0.0010.1 ± 0.50.0 ± 0.2\<0.001Number of patients, *n* (%)135 (2.0)137 (0.3)298 (4.3)387 (0.8)Number of outpatient prescriptionAll cause9.3 ± 6.16.1 ± 5.0\<0.0019.1 ± 3.56.4 ± 3.6\<0.001Number of patients, *n* (%)6707 (97.0)43,813 (92.2)6909 (99.9)47,515 (100.0)Asthma related3.3 ± 4.51.0 ± 2.3\<0.0016.2 ± 5.53.4 ± 3.3\<0.001Number of patients, *n* (%)4242 (61.4)15,140 (31.9)5951 (86.1)44,882 (94.5)The index date was defined as the first date of the highest asthma stage being recorded for a patientData presented as mean ± SD, unless otherwise stated, *ER* emergency room, *SD* standard deviation*P* values were calculated using *χ*^2^ test for categorical variables and *t*-test for continuous variablesFig. 2Incidence rate ratios of HCRU events for severe versus non-severe asthma patients. Data presented as IRR (95% CI). Error bars represent 95% CI values. \**P* \< 0.001 (*P* values were calculated using *χ*^2^ test for categorical variables, *t*-test for continuous variables). IRR is the ratio of incidence rates of all-cause HCRU events in severe and non-severe asthma patients. IRR adjusted for age, gender, insurance type, institution type, baseline comorbidity of interests, and Charlson index score. CI confidence interval, ER emergency room, HCRU healthcare resource utilization, IRR incidence rate ratio

Economic burden---unadjusted and adjusted medical costs {#Sec6}
-------------------------------------------------------

The high HCRU was also reflected from the medical expenditure on these resources. Mean total direct medical costs were significantly higher in the severe asthma cohort than in the non-severe asthma cohort at baseline and the 12-month follow-up (*P* \< 0.001; (*t*-test) Table [3](#Tab3){ref-type="table"}). Furthermore, the medical costs were high in patients in severe asthma cohort relative to those in the non-severe asthma cohort after adjusting for demographics (Fig. [3](#Fig3){ref-type="fig"}).Table 3Mean unadjusted medical cost (all-cause and asthma related) at baseline and follow-upCost in USDBaseline (12 months before index date)Follow-up (12 months after index date)Severe asthma cohort (*N* = 6914)Non-severe asthma cohort (*N* = 47,519)*P* valueSevere asthma cohort (*N* = 6914)Non-severe asthma cohort (*N* = 47,519)*P* valueTotal cost of hospitalizationAll cause1564.8 ± 11,286.08232.5 ± 2144.06\<0.0011277.9 ± 8775.80318.2 ± 3082.74\<0.001Asthma related177.8 ± 2551.0913.2 ± 486.52\<0.001397.2 ± 3562.3152.8 ± 1388.20\<0.001Total cost of ER visitsAll cause94.8 ± 240.8456.6 ± 159.70\<0.001139.2 ± 341.6879.2 ± 201.72\<0.001Asthma related27.2 ± 119.107.9 ± 62.65\<0.00153.4 ± 162.3027.5 ± 119.63\<0.001Total cost of outpatient visitsAll cause1334.8 ± 3401.99645.7 ± 1507.01\<0.0012102.3 ± 4704.60867.8 ± 1738.74\<0.001Asthma related425.0 ± 2210.6388.5 ± 555.85\<0.001789.0 ± 2605.50298.1 ± 1024.23\<0.001Total cost of inpatient prescriptionAll cause211.6 ± 2652.7716.8 ± 374.36\<0.001435.3 ± 1697.0827.6 ± 563.00\<0.001Asthma related40.9 ± 936.261.1 ± 66.30\<0.00188.8 ± 2179.86238.3 ± 624.43\<0.001Total cost of outpatient prescriptionAll cause898.9 ± 2711.46321.1 ± 986.43\<0.0011712.5 ± 4068.71502.3 ± 1167.14\<0.001Asthma related385.4 ± 1629.0863.3 ± 379.24\<0.001868.2 ± 2179.86238.3 ± 624.43\<0.001Total medical costAll cause3404.6 ± 12,506.551083.6 ± 3055.00\<0.0014345.3 ± 11,104.161528.0 ± 3989.21\<0.001Asthma related838.5 ± 3586.13145.1 ± 913.08\<0.0011772.5 ± 4960.14519.6 ± 1889.91\<0.001The index date was defined as the first date of the highest asthma stage being recorded for a patient1 USD = 110 JPY; data presented as mean ± SD*ER* emergency room, *SD* standard deviation*P* values were calculated using *χ*^2^ test for categorical variables and *t*-test for continuous variablesFig. 3Mean adjusted and unadjusted total medical costs for severe versus non-severe asthma patients. Data presented as mean ± standard error. Error bars represent standard errors. 1 USD = 110 JPY

Discussion {#Sec7}
==========

The present study offers real-world evidence on the significant socio-economic burden of asthma in Japan, and confirms a disproportionate concentration of HCRU and asthma-related cost burden in Japanese patients with severe asthma. We identified the main driver of asthma HCRU in Japan to be Step 4 treatment (applied as surrogate marker for severe asthma). Additionally, advanced age and comorbidities were enriched in the severe asthma cohort. This observation suggests that severe asthma patients not only suffer from chronic asthma but also may have a compromised state of health related to multiple factors.

Severe asthma patients constituted 12.7% of the overall asthma population, and were significantly older compared with non-severe asthma patients (43.03 versus 39.76 years; *P* *\<* 0.0001), with 4.4% and 2.2% of patients in the 65- to 74-year-old age group, respectively. Patients within the higher age ranges may represent senior employees or elderly members covered by the employee's family health insurance policy; the proportions of working and non-working seniors is unknown, making a deeper interpretation challenging. Of note, gender differences did not influence any of the study outcomes.

Comorbidities, including infections, allergic rhinitis, sinus disease, and gastroesophageal reflux, which are all known to be associated with uncontrolled asthma were presented more frequently in severe versus non-severe asthma cohort, with pneumonia presenting twice as frequently. On the other hand, COPD was noted in a few patients from both cohorts and the small numbers limited useful interpretation; these patients were not excluded from the analysis to investigate all comorbidities related to asthma. Furthermore, with advancing age, overlapping features of asthma and COPD may become increasingly present.^[@CR17]^ However, the study was not designed to evaluate the relationship between asthma severity and comorbidities.

HCRU was significantly higher in severe asthma patients compared with non-severe patients. Interestingly, increase in IRR and medical costs in the follow-up year were found in both severe and non-severe asthma patients, implying a high medical attendance burden shared across all Japanese patients with asthma. Mean adjusted and unadjusted medial costs were significantly higher in severe asthma patients than in non-severe asthma patients. The healthcare settings from most to least utilized were outpatient visits (the great majority), ER attendance, and finally hospitalization, an expected pattern considering Japan's universal health access. Direct costs provide a partial picture of the disease burden. While this study did not capture indirect costs, one could argue that indirect costs contribute significantly, especially in a working-age population taking into account work productivity losses, quality-of-life deficits, caregiver burdens, and also in special cases of severe asthma, unintended side effects of glucocorticoid therapy.

In recent times, the use of secondary databases such as JMDC has demonstrated utility in assessing drug utilization in various disease areas.^[@CR18]--[@CR20]^ To the best of our knowledge, this is the first study to describe HCRU in adult asthma patients, conducted using a large Japanese population insurance claims database. Results from our study are consistent with prior international evidence. A study by Sullivan et al retrospectively evaluated economic and healthcare utilization as well as sociodemographic characteristics of severe asthma patients in the US from a claims database.^[@CR21]^ Findings from that study were consistent with those from our study; the proportion of severe asthma patients was low, but this subgroup contributed majorly to the economic burden. A report by McDonald et al also highlighted that the care required for the relatively small proportion of severe asthma patients has a major impact on the overall healthcare system.^[@CR22]^ A Japanese prospective study in more than 3600 severe allergic asthma patients, on omalizumab therapy, showed different medical care patterns compared with our study, with approximately 20% and 26% of patients receiving asthma-related care in the hospital and ER, respectively, which was higher than that observed in our study. However, the population demographics of that study differed with respect to age and gender: elevated mean age (59.3 years) with 44% of patients aged \>65 years, and more female patients (64.5%).^[@CR23]^ A comprehensive look at asthma control (which was out of scope for this analysis) considers reducing symptoms, airflow limitation, and exacerbation risks by optimizing inhaler techniques, trigger avoidance, adherence, perception of disease, and appropriateness of therapy versus need for escalation.^[@CR24]^ In the current study, due to its retrospective design using the secondary database, data on above clinical outcomes (e.g., symptoms, lung function) could not be collected, and therefore step-up in therapy offers a reasonable, though incomplete, surrogate measure for loss of disease control in patients in the non-severe asthma cohort.

Strengths of this study include HCRU data generation in a large Japanese population, characterization of severe and non-severe asthma cohorts, and confirmation of age and comorbidities as relevant variables for asthma outcomes. The disposition for 70,000 of \~540,000 total eligible patients was unclear, because these 70,000 patients received prescriptions that were not as per guideline recommendations. This preliminary observation deserves further attention to examine if these patients had only mild intermittent asthma or if they were persistent asthma patients whose treatment regimens could be further optimized. The results highlight a potential deviation from consensus care guidelines, and present an opportunity for further examining real-world clinical practices, especially in an era of biologics and precision medicine when both evidence based and individualized therapies offer novel solutions.

Limitations include retrospective design with its inherent limits, insurance claims are not ideal for clinical questions, variable accuracy for capturing comorbidities, lack of visibility for patient-initiated treatments, off-label use, or over-the-counter alternatives. Drug treatment as a proxy of disease severity is commonly used in commercial claims database analyses and is an acceptable method of classifying patients into disease severity categories.^[@CR16],[@CR25]^ However, asthma severity also considers clinical outcomes that could not be measured in our study, including airflow limitation, intensity of asthma symptoms, or experience of exacerbations. Japanese life expectancy is higher than the world average and a limited representation of patients aged \>65 years could reduce the generalizability of findings to the overall population. Smoking behavior and body mass index have a major impact on asthma severity; however, these variables and others that are important for understanding asthma treatment response, and asthma control, were not included in our analysis.

Overall, the study offers novel real-life evidence in adult patients with asthma in Japan and highlights the need for initiatives to optimize patient care. Appropriate treatment policies, through existing and innovative therapeutic strategies must be designed and implemented to improve clinical outcomes and to reduce HCRU in asthma patients.

The burden of asthma is significantly and disproportionately concentrated in Japanese severe asthma patients, suggesting clinical failure to achieve adequate disease control. This study enhances awareness of current unmet needs in Japan for asthma and provide novel evidence to engage public and private sector stakeholders toward future health solutions.

Methods {#Sec8}
=======

Study design and patients {#Sec9}
-------------------------

This was a retrospective, cohort study in asthma patients from Japan, performed using the JMDC database for the study period from April 2009 to March 2015 (Fig. [4](#Fig4){ref-type="fig"}). An asthma case was defined as any patient claim in the database identified with the disease code J45 (asthma) or J46 (status asthmaticus) as per ICD-10 at minimum two different months during the study period. Asthma severity was defined according to the JSA guidelines^[@CR16]^ recommended drug therapies, with Step 4 corresponding to severe asthma, and Steps 1--3 corresponding to non-severe asthma. Two cohorts were established for comparison, the severe asthma cohort (Step 4 patients) and the non-severe asthma cohort (Steps 1--3 patients). Categorization of asthma patients in Steps 1--4 based on JSA recommended therapies is described in Supplementary Table [2](#MOESM1){ref-type="media"}.

Patients aged ≥16 years with a diagnosis of asthma during the study period were included in the analysis. Eligible patients included employees and their family members covered by their company health insurance plan. They were required to have been enrolled continuously in the database for a minimum of 1 year before (baseline) and 1 year after the index date. The index date was defined as the first date of the highest asthma stage, as per JSA guideline recommendations, recorded for a patient during the study period. Data were collected for a period of 2 years.Fig. 4Study design

The study was approved by the Clinical Research Review Network of the Japan Review Board, Osaka, Japan. This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology^[@CR26]^ Practices of the International Society for Pharmacoepidemiology and with the ethical principles laid down in the Declaration of Helsinki. The study analysis was approved by JMDC. Patient identity was not disclosed. The study is reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations^[@CR27]^ (Supplementary Table [3](#MOESM1){ref-type="media"}).

Data source {#Sec10}
-----------

The JMDC database is the largest public dataset for patient health in Japan and is compiled by health insurance records covering 1.45 million employees and their family members from medium- to large-scale companies.^[@CR15]^ The JMDC database consists of pharmacy and medical claims, and includes demographic data such as year of birth, sex, year and month of medical service or prescription provided, diagnosis based on ICD-10 codes, drug names and dosages, inpatient or outpatient, size of hospital, type of claim, and annual company health check-up data. Retirees aged \>65 years generally drop out of the insurance system at that age; however, elderly patient claims exist, and it is unknown whether they represent senior employees or parents of employees covered under the family insurance plan.

Study outcomes {#Sec11}
--------------

Asthma-specific HCRU was characterized and estimated at baseline and at 12 months after the index date in patients classified in severe and non-severe asthma cohorts based on disease severity. All-cause-related HCRU was also compared in these groups of patients at baseline and at 12 months post index date. Asthma-related and all-cause HCRU was characterized by number of hospitalizations, days in hospitals, prescriptions, ER visits, and outpatient office visits during the study period. IRRs of all-cause HCRU events were adjusted for age, gender, insurance type, institution type, baseline comorbidity of interests, and Charlson index score, and were compared between cohorts. HCRU-associated total costs, which included ER costs, inpatient and outpatient costs, and outpatients' prescription drug costs, were also estimated in these patients. Demographic variables (age, gender, family type), clinical characteristics, and type of medical institution were measured at index date or the closest time before index date.

Statistical analysis {#Sec12}
--------------------

Mean and SD were presented for continuous variables; number of cases and percentages were presented for categorical variables. For categorical variables, *χ*^2^ tests were performed to determine significant differences; for continuous variables, the Wilcoxon rank sum test and the unequal variance two-sample *t*-test were performed. All clinical characterization variables were measured at the time of (or at the time closest to but not exceeding) the index date. The HCRU profiles were characterized by assessments at baseline and at the 12-month follow-up, and comparisons were made between all-cause and asthma-related utilization. IRRs were evaluated using a negative binomial model for count of HCRU events, and presented with 95% CI. Cost was analyzed using a two-part model that included gamma regression following a logistic model and was presented as mean (±SD). Total medical costs were adjusted for age, gender, insurance type, institution type, baseline count outcome, baseline cost, and Charlson index score by using multiple regression models. Statistical analyses were performed using SAS studio 3.4.

Reporting Summary {#Sec13}
-----------------

Further information on research design is available in the [Nature Research Reporting Summary](#MOESM2){ref-type="media"} linked to this article.
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